Platelet-Rich Plasma for Rhinitis Medicamentosa: A Promising Histopathological Study in an Animal Model.

Area of Science:

• Otolaryngology
• Regenerative Medicine
• Histopathology

Background:

• Rhinitis medicamentosa (RM) is a condition characterized by nasal inflammation, often induced by prolonged use of decongestants.
• Histopathological changes, including submucosal edema and gland degeneration, are key indicators of RM severity.
• Current treatments for RM have limitations, necessitating exploration of novel therapeutic approaches.

Purpose of the Study:

• To evaluate the efficacy of platelet-rich plasma (PRP) in ameliorating histopathological changes associated with experimentally induced rhinitis medicamentosa (RM) in a rat model.
• To compare the therapeutic effects of PRP with intranasal corticosteroids and normal saline solution.

Main Methods:

• An experimental animal study was conducted using Wistar albino rats.
• Rhinitis medicamentosa was induced in rats via intranasal oxymetazoline administration.
• Rats were treated with normal saline, corticosteroids, or intranasal platelet-rich plasma (PRP) for 15 days, followed by histopathological analysis of nasal mucosal samples.

Main Results:

• Intranasal PRP treatment significantly reduced submucosal edema and submucosal gland degeneration (SGD) in the nasal mucosa.
• PRP treatment resulted in a greater reduction in the total histopathological score compared to corticosteroid treatment (P=.007).

Conclusions:

• Platelet-rich plasma (PRP) effectively ameliorates key histopathological features of experimentally induced rhinitis medicamentosa.
• PRP demonstrates potential as a promising, autologous treatment option for RM with a low risk of side effects, offering an alternative to steroid therapy.